**ADVISORY COMMITTEE**

**of the Connecticut Bioscience Innovation Fund**

Minutes – Regular Meeting
Wednesday, April 13, 2022

A regular meeting of the **Connecticut Bioscience Innovation Fund** (“the Bioscience Fund” or “CBIF”) **Advisory Committee** (the “Committee”) was held electronically through Microsoft Teams on April 13, 2022.

**1. Call to Order**:

Noting the presence of a quorum, Matt McCooe, Chairperson of the Committee, called the meeting to order at 10:02 a.m.

Committee Members Present: Peter Farina, Ph.D.; Seth Feuerstein; M.D; William LaRochelle, Ph.D.; Chris McLeod, Alan Mendelson; Matt McCooe; Anthony Muyombwe, Ph.D.; Kevin Rakin; David Scheer; Jonathan Soderstrom, Ph.D. and Sandra Weller, Ph.D.

Absent: Charles Lee, Ph.D. and David Lehman.

Staff Attending: Kevin Crowley; Tamyra Davis; Cyndi Greene, Ph.D.; Stepheni Harpin; Malik Lewis; Peter Longo; Jordan Lue; Matthew McCooe; Pauline Murphy; Matt Panicali; Elizabeth Skrabl; Matthew Storeygard; Daniel Wagner; David Wurzer; and Wenping Zhou, Ph.D.

**2. Approval of Minutes:**

Mr. McCooe asked the Committee members to consider the minutes from the March 9, 2022 regular meeting.

**Upon a motion made by Dr.** **Soderstrom and seconded by Dr. Farina, the Advisory Committee members voted** **unanimously in favor of adopting the minutes from the March 9, 2022 regular meeting, as presented.**

*Noting a potential conflict of interest,* *Dr.* *Soderstrom and Mr. McLeod recused themselves from any discussion on Artizan Biosciences, Inc. and left the meeting at 10:02 a.m.*

**3. Follow-On Proposal**

**“****Artizan Biosciences, Inc. – New Haven, CT”**

Mr. Wagner and Dr. Zhou presented the proposed follow-on investment approval request for Artizan Biosciences, Inc. Mr. Wagner then went on to discuss CI’s investment history with the Company.

A discussion ensued.

**Upon a motion made by Mr. Rakin, seconded by Mr. Scheer, the Advisory Committee members voted unanimously in favor of approving financing by the Connecticut Bioscience Innovation Fund (“CBIF”) in an amount of up to TWO HUNDRED FIFTY THOUSAND DOLLARS ($250,000), as presented, in Artizan Biosciences, Inc.**

*At 10:31 a.m., Dr. Soderstrom and Mr. McLeod rejoined the meeting, and Mr. Rakin left the meeting.*

**“BEKHealth Corporation – Kent, CT”**

Mr. Wagner and Dr. Zhou presented the proposed follow-on investment approval request for BEKHealth Corporation. Mr. Wagner then went on to discuss CI’s investment history with the Company.

A discussion ensued.

**Upon a motion made by** **Dr. Feuerstein, seconded by Mr. Mendelson, the Advisory Committee members voted unanimously in favor of approving financing by the Connecticut Bioscience Innovation Fund (“CBIF”) in an amount of up to FIVE HUNDRED THOUSAND DOLLARS ($500,000), as presented, in BEKHealth Corporation.**

*Noting a potential conflict of interest, Mr. McLeod and Mr. Mendelson recused themselves from any discussion on Enrich Therapeutics, Inc. and left the meeting at 10:59 a.m. Mr. Rakin returned to the meeting at 11:00 a.m.*

**“****Enrich Therapeutics, Inc. – Branford, CT”**

Dr. Green and Dr. Zhou presented the proposed follow-on investment approval request for Enrich Therapeutics, Inc. Dr. Green then went on to discuss CI’s investment history with the Company.

A discussion ensued.

**Upon a motion made by Dr. Soderstrom, seconded by Mr. Rakin, the Advisory Committee members voted unanimously in favor of approving the financing by the Connecticut Bioscience Innovation Fund (“CBIF”) in an amount of up to SEVEN HUNDRED FIFTY THOUSAND DOLLARS ($750,000), as presented, and the conversion of outstanding notes in Enrich Therapeutics, Inc.**

*At 11:25 a.m., Mr. McLeod and Mr. Mendelson rejoined the meeting.*

**“****Torigen Pharmaceuticals, Inc. – Farmington, CT”**

Mr. Crowley and Mr. Panicali presented the proposed follow-on investment approval request for Torigen Pharmaceuticals, Inc. Mr. Crowley then went on to discuss CI’s investment history with the Company. Mr. Crowley noted a change to the minimum close from $5 million in the investment proposal to $4 million.

A discussion ensued.

**Upon a motion made by Mr. McLeod, seconded by Dr. Weller, the Advisory Committee members voted unanimously in favor of approving the financing by the Connecticut Bioscience Innovation Fund (“CBIF”) in an amount of up to ONE MILLION DOLLARS ($1,000,000), as presented, and the conversion of outstanding notes in Torigen Pharmaceuticals, Inc.**

**4. Quarterly Update:**

Mr. Storeygard gave a brief presentation on the Pre-Seed and Internal Approvals - CI Ventures Update for the quarter ended March 31, 2022.

**Upon a motion made by Dr. Weller, seconded by Mr. Rakin, the Advisory Committee members voted unanimously in favor of approving the Pre-Seed and Internal Approvals – CI Ventures Update.**

**5. Other Business:**

**CBIF Annual Report**

Mr. Wurzer asked the Committee members for approval of the draft 2022 Annual Report, for immediate filing with the State of Connecticut, as mandated by the Fund’s legislative requirements.

**Upon a motion made by Dr. Soderstrom, seconded by Mr. Rakin, the Advisory Committee members voted unanimously in favor of approving the CBIF Annual Report for the year ended April 15, 2022, as presented.**

**Nobio, Ltd. Update**

Mr. Crowley presented a brief update onNobio, Ltd.

**6. Date of Next Meeting:**

May 25, 2022 at 10:00 a.m.

**7. Adjournment:**

**Upon a motion made by Dr. Weller, seconded by Mr. McCooe, the Advisory Committee members voted unanimously in favor of adjourning the meeting at 11:46 a.m.**

 Respectfully Submitted,

 \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

 Matthew McCooe

 Chairperson